50.00
-0.26(-0.52%)
Currency In USD
| Previous Close | 50.26 |
| Open | 50.2 |
| Day High | 50.42 |
| Day Low | 49.52 |
| 52-Week High | 57.65 |
| 52-Week Low | 29.16 |
| Volume | 455,775 |
| Average Volume | 805,922 |
| Market Cap | 2.87B |
| PE | -147.06 |
| EPS | -0.34 |
| Moving Average 50 Days | 47.81 |
| Moving Average 200 Days | 41 |
| Change | -0.26 |
If you invested $1000 in Supernus Pharmaceuticals, Inc. (SUPN) 10 years ago, it would be worth $4,488.33 as of January 18, 2026 at a share price of $50. Whereas If you bought $1000 worth of Supernus Pharmaceuticals, Inc. (SUPN) shares 5 years ago, it would be worth $1,680.67 as of January 18, 2026 at a share price of $50.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
GlobeNewswire Inc.
Dec 03, 2025 9:05 PM GMT
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 21, 2025 9:06 PM GMT
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 12, 2025 9:05 PM GMT
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to